Quorum-Sensing Inhibitors Emerge as Anti-Virulence Strategy to Combat Antimicrobial Resistance, Enhancing Antibiotic Efficacy

The escalating crisis of antimicrobial resistance (AMR) necessitates novel therapeutic approaches beyond direct bacterial killing. Traditional antibiotics often select for resistance, creating a critical gap in treatment options. Quorum sensing (QS), a sophisticated density-dependent bacterial communication system, orchestrates critical virulence factors, biofilm formation, and metabolic adaptations in many pathogenic bacteria. Targeting QS offers a promising strategy to disarm pathogens, reducing their ability to cause disease and potentially resensitizing them to existing antimicrobials, without exerting direct selective pressure for resistance.

This comprehensive review synthesized current research on quorum-sensing inhibitors (QSIs) as an anti-virulence therapeutic strategy. The authors analyzed studies investigating various QSI types, including naturally occurring compounds, synthetic small molecules, and engineered peptide-based inhibitors. The focus was on their mechanisms of action, such as blocking autoinducer biosynthesis, signal degradation, receptor activation, or downstream transcriptional networks. The review assessed QSI efficacy in preclinical models across diverse pathogens like Pseudomonas aeruginosa, Staphylococcus aureus, and Vibrio species, evaluating their impact on virulence gene expression and biofilm architecture.

The review consistently found that quorum-sensing inhibitors (QSIs) effectively suppress bacterial virulence without direct bactericidal effects. Across numerous preclinical models, QSIs were shown to significantly reduce the expression of virulence genes and disrupt the formation of robust biofilm architectures in pathogens such as Pseudomonas aeruginosa, Staphylococcus aureus, and Vibrio species. This disruption of coordinated bacterial behaviors led to increased susceptibility to conventional antibiotics, suggesting a synergistic potential. > Engineered peptide-based QSIs, alongside small molecules, demonstrated the ability to block autoinducer biosynthesis, degrade signaling molecules, or interfere with receptor activation, thereby preventing the pathogen from mounting a full-scale infection response. Furthermore, QS inhibition was observed to alter the nature of host-pathogen interactions during infection, shifting the balance towards host defense. This anti-virulence approach avoids the direct selective pressure that drives traditional antibiotic resistance.